Date of Award


Document Type


Degree Name

Doctor of Philosophy (PhD)

Legacy Department


Committee Chair/Advisor

Maloney, Michael T

Committee Member

Tollison , Robert

Committee Member

Sauer , Raymond

Committee Member

Warner , John


This paper empirically analyzes how circumstances affect the creation of strategic alliances in the pharmaceutical industry, and the form these alliances take. The models introduced in this paper use the cost of capital and monitoring costs to predict the timing of the deal, which in turn allows the prediction of the deal type. The deal type is then used to predict payment types used in the deal. Deals are characterized by five payment types; upfront, royalty, milestone, equity, and research payments. Deals are also characterized by one of five deal types; co-development, license, acquisition, outsource, and asset purchase. Each of these is a response to a specific contracting problem such as cost of acquiring capital and asymmetric information. The payment types used in pharmaceutical alliances are chosen to efficiently produce monitoring or purchase assets in the face of asymmetric information and to maximize firm profits.

Included in

Economics Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.